Train-of-four
Diagnostic TestPatients submitted to general anesthesia with neuromuscular block will be monitored at their arrival to the Post-Anesthesia Care Unit to assess the presence of residual neuromuscular block.
NCT Number: NCT06386354
The use of neuromuscular blockers (NMB) is essential to optimize surgical conditions, ensure patient immobility during the intervention and prevent complications derived from involuntary movements. Intraoperative monitoring of neuromuscular relaxation allows the depth of neuromuscular blockade to be accurately evaluated, guaranteeing ideal conditions for the surgical team. Residual neuromuscular blockade (RNMB) is the persistence of muscle paralysis after the administration of NMB during a surgical intervention. The appearance of RNMB poses substantial challenges in the postoperative period, as it has negative repercussions for the safety and well-being of the patient.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas, Spain
The use of neuromuscular blockers (NMB) is essential to optimize surgical conditions, ensure patient immobility during the intervention and prevent complications derived from involuntary movements. Intraoperative monitoring of neuromuscular relaxation allows the depth of neuromuscular blockade to be accurately evaluated, guaranteeing ideal conditions for the surgical team. Residual neuromuscular blockade (RNMB) is the persistence of muscle paralysis after the administration of NMB during a surgical intervention. The appearance of RNMB poses substantial challenges in the postoperative period, as it has negative repercussions for the safety and well-being of the patient. In this prospective observational study, all patients who underwent general anesthesia with neuromuscular blockade were studied consecutively to evaluate the presence of residual neuromuscular blockade and its potential consequences during hospital admission.Considering that the percentage of residual curarization is 19% (PORCzero study), with a 95% confidence interval and a 3% error margin, 236 patients are needed to accurately estimate the prevalence of residual curarization in the study population. With an expected loss proportion of 20%, the chosen sample size is 296 patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients submitted to general anesthesia with neuromuscular block will be monitored at their arrival to the Post-Anesthesia Care Unit to assess the presence of residual neuromuscular block.
Time frame: 5 minutes postoperatively
Train-Of-Four ratio at arrival to the Post-Anesthetic Care Unit
Time frame: 8 minutes postoperatively
Train-Of-Four ratio 3 minutes after the arrival to the Post-Anesthetic Care Unit
Time frame: 30 days postoperatively
Postoperative complications during hospital admission
Contact information is provided by the study sponsor or research team.
Aurelio Rodríguez Pérez, PhD
CONTACT
Ángel Becerra Bolaños, PhD
CONTACT
Hospital Universitario de Gran Canaria Doctor Negrín
Other
Acronym: Porcerito
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01509651
Postoperative Neuromuscular Block
Aalst, Belgium
View Trial DetailsNCT07729319
Air Conditioning, Humidification
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07097454
Cardiovascular Diseases, Hypotension
Iksan, Jeollabukdo, South Korea
View Trial DetailsNCT07428057
Calcium Metabolism Disorders, Endocrine Gland Neoplasms
Minya, Minya Governorate, Egypt
View Trial Details